Genmab is licensing a second investigational anti-glycan monoclonal antibody from Scancell as part of an agreement inked between the two companies in 2022. Scancell, a British immunotherapy biotech, announced Wednesday that …
Genmab is licensing a second investigational anti-glycan monoclonal antibody from Scancell as part of an agreement inked between the two companies in 2022. Scancell, a British immunotherapy biotech, announced Wednesday that …